Intellectual Property,
Civil Litigation
Nov. 5, 2020
Induced infringement ruling could have far-reaching effects
A recent Federal Circuit ruling has potentially far-reaching impacts in cases involving allegations of induced infringement.
The U.S. Court of Appeals for the Federal Circuit's recent precedential decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. has potentially far-reaching impacts in cases involving allegations of induced infringement. The court reinstated a jury's verdict that Teva infringed GSK's patented method of using its Coreg drug product, even though Teva's product was initially launched with a skinny label that carved-out the infringing...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In